Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA known ✓ | P10253 | 1/20 | 0.65 |
| ▸ | MAOA known ✓ | P21397 | 1/20 | 0.61 |
| ▸ | CHRM2 known ✓ | P08172 | 1/20 | 0.59 |
| ▸ | SIGMAR1 known ✓ | Q99720 | 3/20 | 0.55 |
| ▸ | DRD4 known ✓ | P21917 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.72 |
| ▸ | MEN1 | O00255 | 2/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.70 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.70 |
| ▸ | MAPT | P10636 | 1/20 | 0.65 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | MPO | P05164 | 2/20 | 0.53 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.53 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.53 |
| ▸ | PKM | P14618 | 1/20 | 0.52 |
| ▸ | THRB | P10828 | 1/20 | 0.50 |
| ▸ | IDO1 | P14902 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19401259 | 0.98 | MEN1 (0.73) | SMN1; SMN2MEN1KMT2ATDP1GAA | |
| SCHEMBL177039 | 0.98 | MEN1 (0.73) | SMN1; SMN2MEN1KMT2ATDP1GAA | |
| Bromide SCHEMBL11864024 | 0.95 | MEN1 (0.70) | SMN1; SMN2MEN1KMT2ATDP1GAA | |
| Alcohol SCHEMBL11200660 | 0.94 | SMN1; SMN2 (0.66) | SMN1; SMN2MEN1KMT2ATDP1GAA | |
| SCHEMBL6265883 | 0.93 | SMN1; SMN2 (0.76) | SMN1; SMN2MEN1KMT2ATDP1GAA | |
| Hydrochloric Acid SCHEMBL8029205 | 0.90 | CHRM2 (0.78) | SMN1; SMN2MEN1KMT2ATDP1GAA | |
| Diethanolamine SCHEMBL5343789 | 0.88 | GAA (0.74) | SMN1; SMN2MEN1KMT2ATDP1GAA | |
| SCHEMBL7986639 | 0.88 | CHRM2 (0.81) | SMN1; SMN2MEN1KMT2ATDP1MAOA | |
| N-Benzylmethylamine SCHEMBL781748 | 0.88 | MAPT (0.63) | SMN1; SMN2MEN1KMT2ATDP1GAA | |
| Sulfuric Acid SCHEMBL28861186 | 0.88 | MEN1 (0.59) | SMN1; SMN2MEN1KMT2ATDP1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118185507-A | Multilayer embossing precoating film and preparation method thereof | 扬州市众和同盛包装材料有限公司 | 2024-06-14 | — | — | CN | claimed |
| CN-115926141-A | Preparation method of cation-pi type coating modified carbon fiber and carbon fiber composite material | 长春工业大学 | 2023-04-07 | — | — | CN | claimed |
| CN-118185507-A | Multilayer embossing precoating film and preparation method thereof | 扬州市众和同盛包装材料有限公司 | 2024-06-14 | — | — | CN | disclosed |
| CN-115058001-B | Retarding monomer and preparation method thereof, retarding water reducer and preparation method thereof | 科之杰新材料集团有限公司 | 2023-08-29 | — | — | CN | disclosed |
| CN-115926141-A | Preparation method of cation-pi type coating modified carbon fiber and carbon fiber composite material | 长春工业大学 | 2023-04-07 | — | — | CN | disclosed |
| CN-112226224-B | Method for increasing crude oil recovery ratio | 中国石油化工股份有限公司 | 2023-03-03 | — | — | CN | disclosed |
| CN-115667339-A | Aqueous polyurethane resin dispersion | 爱克发有限公司 | 2023-01-31 | — | — | CN | disclosed |
| CN-115058001-A | Retarding monomer and preparation method thereof, retarding water reducer and preparation method thereof | 科之杰新材料集团有限公司 | 2022-09-16 | — | — | CN | disclosed |
| CN-114929271-A | Nanoemulsion compositions for the treatment of aeroallergen-related allergies and inflammation | 密歇根大学董事会 | 2022-08-19 | — | — | CN | disclosed |
| CN-112708064-B | Air-entraining and slow-setting type water reducing agent and preparation method thereof | 科之杰新材料集团有限公司 | 2022-07-05 | — | — | CN | disclosed |
| CN-112708067-B | Air-entraining monomer, air-entraining water reducer and preparation method thereof | 科之杰新材料集团有限公司 | 2022-07-05 | — | — | CN | disclosed |
| CN-1948266-B | Method of preparing N-mono substituted benzylamine by catalytic hydrogenation reduction amination | UNIV TSINGHUA | 2010-05-12 | — | — | CN | disclosed |
| CN-1948266-A | Method of preparing N-mono substituted benzylamine by catalytic hydrogenation reduction amination | UNIV TSINGHUA (CN) | 2007-04-18 | — | — | CN | disclosed |
| US-6730784-B2 | AS THERAPEUTIC AGENTS FOR AUTOIMMUNE DISEASES SUCH AS RHEUMATOID ARTHRITIS | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2004-05-04 | — | — | US | disclosed |
| US-20020198376-A1 | Novel urea derivatives | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2002-12-26 | — | — | US | disclosed |
| US-6492370-B1 | Urea derivatives and pharmaceutical compositions thereof | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2002-12-10 | — | — | US | disclosed |
| CN-1299344-A | Novel urea derivatives | SANTEN PHARCEUMATICAL CO LTD (JP) | 2001-06-13 | — | — | CN | disclosed |
| EP-1072591-A1 | NOVEL UREA DERIVATIVES | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2001-01-31 | — | — | EP | disclosed |
| US-4251660-A | Method for preparing tetrahydroisoquinolines | SMITHKLINE CORPORATION (US) | 1981-02-17 | — | — | US | disclosed |
| US-4081030-A | EPOXY RESIN, CURING AGENT, SOLVENT, COUPLING AGENT, QUATERNARY AMMONIUM HALIDE SURFACTANT, AND A PARTICULATE MATERIAL | THE DOW CHEMICAL COMPANY (US) | 1978-03-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020198376-A1 | Novel urea derivatives | TNF, CTH, CFH | GAA 2480/4885MAOA 731/4885CHRM2 315/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.